Although concerns had been raised on the possible association between P2Y12 antiplatelet therapy and solid tumor growth or metastatic dissemination, either follow-up clinical trials or meta-analyses did not point out a significant association between the use of P2Y12 receptor antagonists and cancer incidence or cancer-related death [172,173,174,175]. The gene discussed is P2RY12; the disease is cancer.